Forbeli s.r.o.

Prague 24 trials 11 recruiting

24 Registered trials

11 Currently recruiting

Organisation

Forbeli s.r.o.

Location

Prague, Czechia

Identifier

ORG-100044107

Address

Za Valem 1497/6, 148 00, Czechia

Departments

#40671
FORBELI s.r.o.
N/A
NA
Neurologická ambulance
Neurology
Neurology Ambulance
neuropsychiatrie
not applicable

Clinical trials at this site (24)

Search interface

A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into… Not authorised

2022-501644-15-00 Mild Cognitive Impairment due to Alzheimer's Disease Al 4
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520746-30-00 Mild to moderate Alzheimer’s Disease 5 2025-11-18
Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures Recruiting

2024-514499-42-00 Refractory Partial Onset Epilepsy 5 2025-03-12
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alz… Recruiting

2022-503148-41-00 Alzheimer's disease 4 2023-12-01
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease Recruiting

2024-516966-12-00 Alzheimer’s disease 4 2026-02-13
A study to investigate the safety and efficacy of MEDI0618 compared to placebo in adult participants with episodic migraine Recruiting

2024-512904-21-00 Migraine 4 2025-12-10
A Phase 2a, Multi-Center, Randomized, Parallel Group, Double Blind and Placebo-controlled Clinical Trial to Assess Safety and Tolerability a… Recruiting

2024-518563-35-00 Alzheimer's Disease 4 2025-08-25
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP. Recruiting

2023-507351-29-00 Alzheimer's Disease Psychosis 5 2024-12-03
An Open-label Study of XEN1101 in Epilepsy Recruiting

2022-502282-24-00 Primary generalized tonic-clonic seizures 5 2024-02-14
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Recruiting

2022-502281-25-00 Focal Onset Seizures 5 2023-09-27
An extension study to learn if Staccato Alprazolam is safe when treating long seizures in children ≥12 years of age and adults Recruiting

2023-508868-30-00 Treatment of stereotypical prolonged seizure 5 2022-09-26
An outpatient study to learn if Staccato Alprazolam is safe and effective when treating long seizures in children ≥12 years of age and adult… Recruiting

2024-510950-29-00 Stereotypical prolonged seizure 5 2022-07-21
ACP-204 in Adults with Alzheimer’s Disease Psychosis Ended

2023-507325-42-00 Alzheimer Disease psychosis 4 2024-07-02
A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei… Ended

2023-508306-15-00 Alzheimer’s Disease 5 2024-06-26
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe… Ended

2022-501644-15-01 Mild Cognitive Impairment due to Alzheimer's Disease Al 4 2023-09-28
A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended

2023-508821-28-00 Migraine 4 2024-08-14
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain Ended

2023-506127-29-00 Diabetic Peripheral Neuropathy 4 2024-03-05
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended

2023-505396-71-00 Early Alzheimer’s Disease with Biomarkers of Inflammati 4 2024-03-01
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended

2022-502000-73-00 Focal Onset Seizures 5 2023-08-11
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effe… Ended

2023-510317-26-00 Amyotrophic Lateral Sclerosis 4 2023-02-07
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended

2023-507096-21-00 Chronic or Episodic Migraine (Migraine without aura, mi 5 2021-08-16
A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product … Ended

2024-512123-37-00 Parkinson's disease 5 2021-05-27
EQU-001 as an Add-On Drug for People with Focal Seizures while on Medication Ended

2022-500302-18-00 Epilepsy 4